KalVista Pharmaceuticals, Inc. - מכפיל EV/Sales KALV

KalVista Pharmaceuticals (KALV) relies on future sales of oral treatments for hereditary angioedema. The business viability is currently directly tied to drug certification and clinical trial results. Experienced management is actively preparing for the commercial launch of the flagship product. The EV/Sales ratio confirms market expectations, with the current value equal to 1004727.27, reflecting the current business valuation relative to revenue.
KALV (KalVista Corp): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator determines the market value of the business, accounting for net debt relative to generated revenue. By analyzing the enterprise value-to-sales multiple, an investor gains a real assessment of assets without distortions from the capital structure. The trend line reflects market expectations regarding future cash flows. For KalVista Pharmaceuticals (KALV), a high valuation is justified by the development of a unique oral drug. Inelastic demand for edema therapy will provide the company with exceptional pricing power.